Allorion Therapeutics Co. Ltd. has patented nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus.